Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions

9 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
A virtual roundtable, hosted by Dr. Petros Grivas of Fred Hutchinson Cancer Center, contextualized the latest bladder cancer research updates and trials of relevancy to come out of the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. Dr. Grivas was joined by Drs. Guru Sonpavde, Elizabeth Plimack, Christopher Wallis, Terence Friedlander, and Matthew Galsky.

In the fourth segment of the roundtable, the panel shares the NIAGARA trial's findings, expressing cautious optimism while raising concerns about the universal use of adjuvant therapy, while also highlighting promising results from the RETAIN-2 trial on dose-dense MVAC for bladder preservation. The conversation also covers the potential approval of durvalumab in the neoadjuvant-adjuvant setting, addressing patient selection challenges, and suggesting that immunotherapy may benefit both pathologic complete responders and non-responders.
Category
Oncology
Be the first to comment

Up Next